FDA Declines to Approve Evolus Inc ' s Rival Treatment to Botox FDA Declines to Approve Evolus Inc ' s Rival Treatment to Botox

U.S. health regulators on Wednesday declined to approve Evolus Inc ' s rival product to Allergan Plc ' s Botox, citing certain deficiencies related to its potential treatment for frown lines.Reuters Health Information
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Plastic Surgery & Aesthetic Medicine News Source Type: news